Business Context and Reporting Period
This Form 8-K is a current report filed by PharmAthene, Inc. (not Altimmune, Inc.) on March 25, 2010. The filing reports on corporate governance changes and upcoming shareholder meeting logistics.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial data disclosed relates to a specific executive compensation grant:
- Stock Option Grant: 100,000 shares granted to Eric I. Richman.
- Exercise Price: $1.51 per share (closing price on March 25, 2010).
- Vesting Schedule: 25% annually over four years.
- Expiration Date: March 25, 2020.
Material Changes
Executive Promotion: Eric I. Richman was promoted from Senior Vice President, Business Development & Strategic Planning, to President and Chief Operating Officer, effective March 25, 2010. He now oversees all day-to-day operations.
Shareholder Meeting Date Change: The 2010 Annual Meeting of Stockholders is scheduled for June 23, 2010. This date is more than 30 days prior to the anniversary of the 2009 meeting, triggering specific notice requirements for stockholder proposals.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of risks and contingencies. It notes that stockholder proposals for inclusion in the proxy statement must be received by April 9, 2010, to comply with Rule 14a-8.
Investor Verification Checklist
- Verify the correct registrant name is PharmAthene, Inc., not Altimmune, Inc.
- Confirm the new reporting structure under President and COO Eric I. Richman.
- Note the April 9, 2010 deadline for submitting stockholder proposals for the June 23, 2010 Annual Meeting.
- Review the attached press release (Exhibit 99.1) for additional context on the executive promotion.